Gene therapy is finally getting a bumper crop of data that show clinical efficacy after fine-tuning of key parameters that control safety and potency. Supporting evidence comes from treatment of two life-threatening human diseases.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Self-assembly of c-myc DNA promoted by a single enantiomer ruthenium complex as a potential nuclear targeting gene carrier
Scientific Reports Open Access 06 July 2016
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Biffi, A. et al. Science http://dx.doi.org/10.1126/science.1233158 (2013).
Aiuti, A. et al. Science http://dx.doi.org/10.1126/science.1233151 (2013).
Naldini, L. Nature Rev. Genet. 12, 301–315 (2011).
Cartier, N. et al. Science 326, 818–823 (2009).
Cavazzana-Calvo, M. et al. Nature 467, 318–322 (2010).
Boztug, K. et al. N. Engl. J. Med. 363, 1918–1927 (2010).
Tubsuwan, A. et al. Stem Cells http://dx.doi.org/10.1002/stem.1436 (2013).
Rights and permissions
About this article
Cite this article
Leboulch, P. Primed for take-off. Nature 500, 280–282 (2013). https://doi.org/10.1038/500280a